News & Updates

Treatment of gestational diabetes before 20 weeks’ gestation appears to lead to a modestly lower incidence of a composite of adverse neonatal outcomes as compared with no-immediate treatment, with no substantial differences noted for pregnancy-related hypertension or neonatal lean body mass, as reported in a study.

Treatment with the immune checkpoint inhibitor avelumab in the second-line setting confers survival and disease control benefits in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) when compared with standard treatment, with a favourable safety profile, according to the results of the phase II SAMCO-PRODIGE 54 trial.

In the treatment of individuals with uncomplicated urinary tract infection (UTI), the use of antibiotics with lower reported resistance rates such as amoxicillin-clavulanate and nitrofurantoin (AC + N) lowers the rate of treatment failure, as shown in a study from Singapore.

Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) albiglutide results in fewer cardiovascular events, irrespective of sodium-glucose cotransporter-2 (SGLT2) inhibitor use, among patients with type 2 diabetes (T2D) and cardiovascular disease, according to the post hoc analysis of Harmony Outcomes*.

Eating nuts on a regular basis provides neuroprotective benefits to older adults who are overweight or obese, have metabolic syndrome, and are predisposed to memory loss or confusion, results of a cohort study have shown.

Comorbid major depressive disorder and rapid eye movement sleep behaviour disorder (MDD-RBD) is a common subtype of MDD. These patients and their first-degree relatives (FDRs) are at risk of neurodegeneration, researchers from the Chinese University of Hong Kong (CUHK) have reported.